Abstracts tagged "fibromyalgia"

Abstract Number: 1245 • ACR Convergence 2025
Efficacy And Safety of Low-dose Naltrexone In Fibromyalgia: An Updated Systematic Review And Meta-Analysis of Randomized Controlled Trials (RCTs)
Rubab Rizwan, Sehneet Grewal, Sri Varsha Banda and Mohammad Hazique, Nuvance Health, poughkeepsie, NY
Background/Purpose: Fibromyalgia is a chronic condition marked by widespread pain that can significantly reduce a patient’s quality of life. While low-dose naltrexone (LDN) has emerged…
Abstract Number: 0225 • ACR Convergence 2025
Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses
Juan Schmukler¹, Tengfei Li² and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: Comorbid anxiety (ANX), depression (DEP), and fibromyalgia(FM) are reported as more common in patients with rheumatoid arthritis (RA) and other rheumatic diagnoses than in…
Abstract Number: 1244 • ACR Convergence 2025
PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems
Rosemary Hollick¹, Marcus Beasley¹, Ernest Choy², Caroline Cupit³, Debra Dulake¹, Teresa Finlay³, Louise Locock¹, Paul McNamee¹, Catherine Pope³, Elaine Wainwright¹, David Williams⁴ and Gary Macfarlane¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ³University of Oxford, Oxford, United Kingdom, ⁴University of Michigan, Michigan
Background/Purpose: Fibromyalgia is a contested and poorly supported condition, characterised by widespread pain, fatigue, and cognitive symptoms, often compounded by stigma and delayed diagnosis. Existing…
Abstract Number: 0197 • ACR Convergence 2025
Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
Theodore Pincus¹, Juan Schmukler¹ and Tengfei Li², ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: A symptom checklist and screening indices for anxiety (ANX), depression (DEP), and/or fibromyalgia (FM) on patient questionnaires such as a multidimensional health assessment questionnaire…
Abstract Number: 1242 • ACR Convergence 2025
Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants
Robert Katz¹, Alexandra Katz Small², Edwin Moore³ and Seth Adler⁴, ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, CHICAGO, IL, ³University of Illinois Urbana Champaign, CHICAGO, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is a multifaceted disorder defined by chronic widespread pain, sleep disruption, fatigue, and cognitive difficulties. Although the predominant theory behind FM pathogenesis…
Abstract Number: 1243 • ACR Convergence 2025
Broad Cytokine Dysregulation in Fibromyalgia Patients: A Pilot Immune Profiling Study
Robert Katz¹ and Alexandra Katz Small², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, CHICAGO, IL
Background/Purpose: Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, cognitive disturbances, and poor sleep. Despite accumulating evidence of immune involvement, a…
Abstract Number: 1237 • ACR Convergence 2025
Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management
Michael Rosenbluth¹, Yifei Dai¹, Dianne Shumay¹ and Andrea Chadwick², ¹Swing Therapeutics, San Francisco, CA, ²University of Kansas School of Medicine, Kansas City, KS
Background/Purpose: Guidelines for fibromyalgia treatment recommend non-pharmacologic treatment, including cognitive behavioral therapy, alongside medications [1-3]. However, patient access to multi-modal treatment is frequently limited due…
Abstract Number: 1236 • ACR Convergence 2025
Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
Michael Kaplan¹, Alexandra Canori², Rebecca Howard², Talia Torkian³, Rebecca Pietro¹, Gabriela Santiago-Pichardo¹, Daniel Clauw⁴, David Putrino², Yousaf Ali¹, Laura Tabacof² and Trung Ngo⁵, ¹Division of Rheumatology, Mount Sinai Hospital, New York, ²Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, ³Division of Rheumatology, Icahn School of Medicine at Mount sinai, New York, ⁴Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ⁵RECOVER Injury Research Centre, The University of Queensland and Surgical, Treatment & Rehabilitation Service (STARS), Queensland, Australia
Background/Purpose: Fibromyalgia (FM) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are prototypical nociplastic disorders marked by centralized pain & fatigue, respectively. Nociplastic symptoms — such as…
Abstract Number: 1234 • ACR Convergence 2025
Serum Antibodies Against Glial Fibrillary Acidic Protein in Fibromyalgia: A Proof-of-Concept Study
Felipe Massó¹, Laura Aline Martinez-Martinez², Luis M Amezcua-Guerra³, Francisco Mercado⁴, Angélica Almanza⁵ and Manuel Martínez-Lavín¹, ¹Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ²Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico, ³Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, ⁴Instituto Nacional de Psiquiatría Ramón del la Fuente Muñiz, Mexico city, Mexico, ⁵Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico city, Mexico
Background/Purpose: Fibromyalgia (FM) is a stress-related disorder in which dorsal root ganglia (DRG) may play a pivotal pathogenetic role. DRG exhibit unique stress-induced, pro-algesic physio-anatomy,…
Abstract Number: 1231 • ACR Convergence 2025
TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
Gregory Sullivan¹, Errol Gould², Mary Kelley¹, Jean Engels¹ and Seth Lederman³, ¹Tonix Pharmaceuticals, Inc., Chatham, NJ, ²Tonix Pharmaceutical, Inc., Henderson, NV, ³Tonix Pharmaceuticals, Inc., Austin, TX
Background/Purpose: FDA-approved treatments for fibromyalgia (FM) have historically been limited by intolerable side effects that often lead to poor adherence. TNX-102 SL, a sublingual formulation…
Abstract Number: 1228 • ACR Convergence 2025
Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Brennan Spiegel¹, Jeffrey Curtis², Yashar Eshraghi³, Maged Guirguis³, Beth Darnall⁴, Christine Rini⁵, Emily Holladay⁶, Mehra Muskaan¹, So Yung Choi¹ and Samuel Eberlein¹, ¹Cedars Sinai, Los Angeles, CA, ²Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ³University of Queensland Ochsner Medical School, New Orleans, LA, ⁴Stanford University School of Medicine, Palo Alto, CA, ⁵Northwestern University, Chicago, IL, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Evidence-based behavioral treatments for chronic pain are largely inaccessible, particularly to rural patients. This decentralized randomized controlled trial compared the effectiveness of two digital,…
Abstract Number: 1220 • ACR Convergence 2024
Fibromyalgia’s Under-Representation in Rheumatology Literature: A Ten-Year Analysis of Disease-Specific Article Distribution
Seth Adler¹, Osama Al Zoubi² and Robert Katz³, ¹Rheumatology Associates, Rush University Medical Center, Chicago, ²University of Illinois at Chicago, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Recent estimates predict that up to 12 million adults in the United States suffer from Fibromyalgia Syndrome (FMS). That is compared to around 1.3…
Abstract Number: 0327 • ACR Convergence 2024
Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies
Samuel Govea-Peláez¹, Beatriz Alcalá-Carmona², Jennifer Balderas Miranda³, Yatzil Reyna-Juárez², María José Ostos-prado², Nancy R Mejía-Domínguez², Guillermo Juarez-Vega⁴, Jiram Torres Ruiz⁵ and Diana Gomez-martin⁶, ¹INCMNSZ, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ³Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Mexico, Federal District, Mexico, ⁶INCMNSZ, Mexico City, Federal District, Mexico
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…
Abstract Number: 1221 • ACR Convergence 2024
Efficacy of Immersive Virtual Reality-based Biofeedback on Chronic Pain and Daily Life Impact in Fibromyalgia: A Pilot Randomized Controlled Trial
Luca Chittaro¹, Simone Longhino², Marta Serafini¹, Sofia Cacioppo² and Luca Quartuccio³, ¹Human-Computer Interaction Lab, Department of Mathematics, Computer Science and Physics, University of Udine, Udine, Italy, ²Division of Rheumatology, Department of Medicine, University of Udine, UDine, Italy, ³Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy
Background/Purpose: Fibromyalgia (FM) affects 2% of the global population, causing chronic musculoskeletal pain, fatigue, sleep and mood disorders, significantly impacting quality of life. Although many…
Abstract Number: 0561 • ACR Convergence 2024
Axial Spondyloarthritis Patients with Comorbid Fibromyalgia Feel Worse, Work Less and More Often Try Multiple Biological DMARDs − Results from a Population-Based Cohort
Annie Brink¹, Elisabeth Mogard², Elisabet Lindqvist², Jonas Sagard², Johan Karlsson Wallman¹ and Tor Olofsson², ¹Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ²Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden
Background/Purpose: A growing arsenal of biologic/targeted synthetic DMARDs often makes inflammation control an attainable target in axial spondyloarthritis (axSpA). Yet, many patients keep suffering from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].